Virax Biolabs Group Limited (NASDAQ: VRAX)
$2.4100
+0.0700 ( -11.72% ) 352.4K
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Market Data
Open
$2.4100
Previous close
$2.3400
Volume
352.4K
Market cap
$10.16M
Day range
$2.1700 - $2.9450
52 week range
$0.6000 - $8.9999
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Form 6-K | 1 | Dec 23, 2024 |
6-k | Form 6-K | 2 | Dec 17, 2024 |
6-k | Form 6-K | 2 | Dec 10, 2024 |
6-k | Form 6-K | 3 | Nov 20, 2024 |
6-k | Form 6-K | 8 | Oct 31, 2024 |
6-k | Form 6-K | 2 | Oct 23, 2024 |
6-k | Form 6-K | 2 | Sep 30, 2024 |
6-k | Form 6-K | 6 | Aug 23, 2024 |
20-f | Annual reports | 106 | Aug 20, 2024 |
nt | Quarterly Reports | 1 | Aug 01, 2024 |